Phase 3 N=105 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma · Retinal Neoplasm
Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=30 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure
Phase 4 N=26 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Retinoblastoma
Primary: Event Free Survival Rate — 7; 4 participants — p=0.034
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 3 N=60 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Phase 3 N=28 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Phase 3 N=331 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 0.9394; 0.9953 Estimated Probability
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
N/A N=1 Treatment With Intravitreal Avastin for Large Uveal Melanomas
Uveal Melanoma
Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants
N/A N=197 Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia
Exotropia
Primary: Number of Participants With Suboptimal Surgical Outcome as Assessed by Motor Alignment and Stereoacuity at Near by 3 Years — 43; 33 Participants — p=0.24
N/A N=40 Symmetric vs Asymmetric BLR Recession in Management of Basic IXT With Ocular Dominance
Intermittent Exotropia
Primary: Ocular Alignment at Distant Fixation — 5.8; 1.1 prism diopter
Phase 2 N=9 RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants
Phase 2 N=47 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Recurrent Uveal Melanoma · Stage III Uveal Melanoma AJCC v7 · Stage IIIA Uveal Melanoma AJCC v7
Primary: Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4) — .323; .267 proportion of participants — p=0.70
Phase 2 N=8 Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Choroidal Melanoma
Primary: To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal…
N/A N=44 Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect
Multiple Sclerosis · Glaucoma
Primary: Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD) — 44; 37 participants
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 2 N=5 RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Age Related Macular Degeneration
Primary: Macular Edema — 416 Microns
Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Phase 2 N=22 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Scleritis · Orbital Disease
Primary: Reduction of Medications — 5; 4 participants
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 1 N=120 Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Phase 2 N=87 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Thyroid Associated Ophthalmopathies · Thyroid-Associated Ophthalmopathy
Primary: Responder Status at Week 24 — 9; 29; 36; 13 Participants — p=< 0.001
Phase 2 N=37 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 — 2; 18; 14; 1 Participants